Congress Program

Monday, 25 June

 07:30 Registration 
 08:25
Congress Opening and 
Welcome Address
Jacob Schachter, Director, The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Israel

 08:30
Paradigm Shift in Modern Oncology
Jacob Schachter,
Director, The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Israel
Sponsored by BMS

 09:00
Basic Immunology
Michal Besser,
Head of Laboratory, Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Israel

 09:45
Unleashing the Immune System Against Cancer
Gal Markel, Chief Scientist, Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Israel

 10:30
Coffee Break, Poster Viewing and Visit the Exhibition

 11:00
Cell α Gene Therapy
Michal Besser, Head of Laboratory, Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Israel

 11:45
Two Sides of the Mirror – Autoimmunity and Cancer Immunotherapy
Paolo AsciertoDirector, Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Tumor Institute, Naples, Italy

 12:15
Bacterial Ghosts in Immunotherapy of Cancer
Werner Lubitz, CEO / CSO, BIRD-C GmbH & Co KG, Austria

 12:45
Lunch Break, Poster Viewing and Visit the Exhibition

 13:45
Cancer Immunotherapy : Blazing the Trail with Melanoma
Caroline Robert
Head, Dermatology Unit, Gustave-Roussy Institute, France

 14:15
Current Treatment of Advanced Melanoma
Ronnie Shapira-Frommer, Oncologist, Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Israel
Novartis Independent Sponsorship


 14:45
Translational Immune Oncology
Paolo Ascierto, Director, Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Tumor Institute, Naples, Italy

 15:15  
Coffee Break, Poster Viewing and Visit the Exhibition

 15:40
Melanoma Case Study
Nethanel Asher, Oncology Specialist, Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Israel

 16:10
Oral Presentations from Selected Abstracts

16:10-16:20
AptaAnalyzer™- A New NGS Software Tool for Improved Acquisition and Analysis of Immune Signatures
Michael Blank, Christian Grohmann, Germany

16:20-16:30
Patterns of TIGIT Expression in Normal Lymphatic Tissue, Inflammation and Cancer
Wenchao Li, Niclas Blessin, Ronald Simon, Martina Kluth, Kristine Fischer,
Claudia Hube-Magg, Georgia Makrypidi-Fraune, Björn Wellge, Tim Mandelkow,
Nicolaus Debatin, Doris Höflmayer, Guido Sauter, Sarah Minner, Franziska Büscheck,
Ria Uhlig, David Dum, Till Krech, Andreas Lübcke, Corinna Wittmer, Frank Jacobsen,
Eike-Christian Burandt, Stefan Steurer, Waldemar Wilczak, Andrea Hinsch, Germany

16:30-16:40
Durable Remissions Associated with Anti-CTLA-4 and Anti-PD1 Checkpoint Inhibitors in a Single Center
Bernardo Rapoport, Teresa Smit, Ronwyn Van Eeden, South Africa

16:40-16:50
Innate Immunity Based Therapy of Melanoma and Pancreatic Adenocarcinoma in Murine Model
Jan Zenka, Veronika Caisova, Ondrej Uher, Pavla Nedbalova, Karolina Kvardova,
Kamila Masakova, Gabriela Krejcova, Lucie Padoukova, Ivana Jochmanova,
Jindrich Chmelar, Jan Kopecky, Czech Republic

16:50-17:00
Predictive Personalized Monitoring of Tryptophan Metabolism and Neopterin in the Treatment of Cancer with Immune Checkpoint Inhibitors
Johanna Gostner, Simon Geisler, Marlies Stonig, Dietmar Fuchs, Austria
 17:00  
End of Day One


Tuesday, 26 June


08:30  Registration 
09:00
Advanced Combinations of Immunotherapy – Current Knowledge and Future Plans
Dirk Schadendorf, Professor of Dermatology, University Hospital Essen, Germany

09:45 
NSCLC Case Study and Update on Immunotherapy in Lung Cancer
Arnold Cyjon, Deputy Director of the Oncology Institute, Assaf Harofeh Medical Center, Israel

10:30
Coffee Break, Poster Viewing and Visit the Exhibition

11:00
Immunotherapy for Patients with High MSI Tumors
Gal Markel, Chief Scientist, Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Israel

11:45
Immunotherapy of RCC and Urothelial Cancers and Case Study
Daniel Keizman
Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Israel

12:15
Resistance Mechanism of Immunotherapy
Gal Markel, Chief Scientist, Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Israel

12:45
Lunch Break, Poster Viewing and Visit the Exhibition

13:45
Oral Presentations from Selected Abstracts

13:45-13:55
Investigating the Feasibility of Tumour Infiltrating Lymphocyte Therapy for Paediatric Malignancies with High Risk and Poor Prognosis
Gray Kueberuwa, Chitra Sethuraman, Edmund Cheesman, Ian Kamaly-Asl,
John-Paul Kilday, Robert Hawkins, UK

13:55-14:05
APN401: Individual Cellular Immunotherapy Based on the Intracellular Master Checkpoint cbl-b
Hans Loibner, Guenther Lametschwandtner, Kerstin Westritschnig, Alexander Dohnal, Oliver Mutschlechner, Marc Salzberg, Pierre Triozzi, Austria

14:05-14:15
Effectivity of Long Antigen Exposition Dendritic Cell Therapy (Lanex-DC®) in the Adjuvant Treatment of Rectal Cancer
Frank Gansauge, Germany

14:15 
Case Studies
Nethanel Asher and Guy Ben-Betzalel
 
15:15
Coffee Break, Poster Viewing and Visit the Exhibition

15:30
Case Studies
Ronnie Shapira-Frommer and Gal Markel

 16:30
Closing Remarks
Jacob Schachter, Congress Chair


Install Google Tag Manager Copy the code below and paste it on to every page of your website. Paste this code as high in the of the page as possible: Additionally, paste this code immediately after the opening tag: For more information about installing the Google Tag Manager snippet, visit our Quick Start Guide .